SCHEMBL10110050

SCHEMBL10110050

C=C(O)C1(c2ccc(C)c(C)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.42
ESR1 P03372 4/20 0.42
ESR2 Q92731 3/20 0.42
AKR1B10 O60218 1/20 0.40
AKR1C4 P17516 1/20 0.40
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
AKR1C1 Q04828 1/20 0.40
CYP2C19 P33261 1/20 0.36
MCL1 Q07820 1/20 0.33
ACHE P22303 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
NPSR1 Q6W5P4 2/20 0.31
ALDH1A1 P00352 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10110060 0.81 AKR1C1 (0.57) CCR2AKR1B10AKR1C4AKR1C3AKR1C2
SCHEMBL18400355 0.75 CCR2 (0.33) CCR2ESR1ESR2AKR1B10AKR1C4
SCHEMBL14403441 0.72 CYP3A4 (0.42) CCR2AKR1C3AKR1C2AKR1C1CYP2C19
SCHEMBL13365075 0.72 TSHR (0.42) ESR1ESR2AKR1C3AKR1C2AKR1C1
SCHEMBL11959487 0.71 ESR2 (0.46) ESR1ESR2AKR1C1CYP2C19MEN1
SCHEMBL18213720 0.69 LMNA (0.42) MEN1KMT2AALDH1A1LMNAMAPT
SCHEMBL16168284 0.69 ESR1 (0.33) ESR1ESR2
SCHEMBL12283199 0.67 CFTR (0.46) ADORA3ADRA1A
SCHEMBL24425967 0.67 CYP2C19 (0.40) CCR2ESR1ESR2AKR1B10AKR1C4
SCHEMBL11802976 0.67 SLC6A4 (0.37) CCR2ESR1ESR2CYP2C19SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586615-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-19 US disclosed
US-20120010257-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 US disclosed
US-20080161371-A1 Modulators of cystic fibrosis transmembrane conductance regulator FIRST-CITIZENS BANK & TRUST COMPANY 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010257-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B CCR2 1097/4885ESR1 3987/4885ESR2 2090/4885
US-20080161371-A1 Modulators of cystic fibrosis transmembrane conductance regulator CFTR, SCNN1G, SCNN1B CCR2 1097/4885ESR1 3987/4885ESR2 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.